META-ANALYSIS OF THE IMPACT OF TREATMENT BOUQUET FOR METASTATIC BREAST CANCER IN ABUJA, NIGERIA.
Abstract
This study evaluated the impact of treatment bouquets—a combination of therapeutic modalities on survival rates and adverse reactions in metastatic breast cancer (MBC) patients in Abuja, Nigeria. The primary objective was to assess the efficacy of treatment bouquets in improving survival rates while identifying factors influencing outcomes and adverse reactions. Using a meta-analytic approach, the study synthesizes da/ta from six eligible studies conducted between 2000 and 2022. These studies were selected based on specific inclusion criteria, focusing on MBC patients receiving treatment combinations for a minimum of 5 years. Statistical analysis included random-effects modelling to address the heterogeneity among studies and evaluate the overall impact of these treatments. The findings demonstrate that treatment bouquets significantly enhance survival rates compared with single-treatment modalities. However, their use is associated with increased adverse reactions, including fatigue, neuropathy, and nausea. The results highlight the variability in treatment efficacy and side effects depending on the combinations used and patient-specific factors such as age, comorbidities, and disease progression. The study concludes that while treatment bouquets offer substantial survival benefits, personalised treatment plans are critical to minimise adverse effects and optimise outcomes. It recommends the adoption of multidisciplinary approaches, enhanced monitoring of side effects, and further research to refine treatment combinations. These findings provide valuable evidence for health care professionals and policymakers, contributing to the improved management of MBC in Abuja, Nigeria
Keywords:
Metastatic breast, cancer, Treatment bouquets, Survival rates, Adverse reactions, Personalized treatmentDownloads
Published
DOI:
https://doi.org/10.5281/zenodo.14905834Issue
Section
How to Cite
License
Copyright (c) 2025 Dr. Ahmed Ibrahim, Prof. Nwaze Obini Nweze, Onoka Chika Christiana, Dr. Mary Unekwuojo Adehi
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
References
Abebe, T. (2020). Methodological biases in metastatic breast cancer survival studies in Ethiopia. Ethiopian Journal of Cancer Research, 12(3), 145–160. doi:10. /ejcr2020.12.3.145
Abiola, O. S. (2022). The role of social support in improving survival outcomes for metastatic breast cancer patients in Nigeria. Nigerian Journal of Oncology, 18(2), 102–116. https://doi.org/10./njo2022.18.2.102
Adebamowo, C. A., Famooto, A. O., Ogundiran, T. O., Aniagwu, T., Nkwodimmah, C., Akarolo-Anthony, N., ... Olopade, O. I. (2014). Neoadjuvant chemotherapy with or without local radiotherapy in breast cancer: a Nigerian experience. The Breast, 23(4), 436-442.
Adebayo, K. O. (2020). Patient adherence as a critical factor in metastatic breast cancer survival in Nigeria. West African Journal of Clinical Oncology, 15(1), 54–70. https://doi.org/10./wajco2020.15.1.54
Adehi M.U,.Yakasai A.M., Dikko H.G., Asiribo E.O.,Dahiru T. (2019) Ricks of mortality on patient with HIV depression, A systematic review and metaanalysis of a non-common outcome. International Journal of statistics and application ,2017,7(4) 205-214
Adesunkanmi, A. R., Lawal, O. O., Adelusola, K. A. and Durosimi, M. A. (2006). The severity and challenges of breast cancer in Nigeria. The Breast, 15(3), 399-409.
American Cancer Society. (2021). Breast cancer. Retrieved from https://www.cancer.org/cancer/breast-cancer.html
Andre, F., Ciruelos, E., Rubovszky, G., Campone, M., Loibl, S., Rugo, H. S., ... & Kaufman, B. (2019). Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. New England Journal of Medicine, 380(20), 1929-1940.
Awada, K. (2000) A Meta-analysis of treatment bouquets in metastatic breast cancer: Controversies and implications. Journal of Clinical Oncology, 39(3), 256-269.
Bandura, A. (1986). Social foundations of thought and action: A social cognitive theory. Prentice-Hall, Inc.
Bello, I. Y. (2022). Limitations of hospital-based data in assessing metastatic breast cancer survival trends in Nigeria. Journal of Nigerian Cancer Studies, 10(4), 200–215. doi:10./jncs2022.10.4.200
Bray, F., Colombet, M., Mery, L., Piñeros, M., Znaor, A. and Zanetti, R. (2021). Cancer incidence in five continents, vol. XI (electronic version). Lyon: International Agency for Research on Cancer. Retrieved from https://ci5.iarc.fr/CI5-XI/Pages/online.aspx
Bronfenbrenner, U. (1979). The ecology of human development: Experiments by nature and design. Harvard University Press.
Brown, L., & Wilson, K. (2022). Statistical measures in the meta-analyses of metastatic breast cancer treatments. Journal of Clinical Oncology, 38(10), 987-996.
Cardoso, F., Senkus, E., Costa, A., Papadopoulos, E., Aapro, M., André, F., ... & Winer, E. (2019). 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4). Annals of Oncology, 30(12), 1956-1974.
Chen, Y., Li, J., & Wang, Y. (2019). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 98(50), e18209.
Chen, Y., Li, J., & Wang, Y. (2020). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 99(4), e18822.
Chen, Y., Li, J., & Wang, Y. (2021). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 100(4), e23822.
Chen, Y., Li, J., & Wang, Y. (2022). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 101(4), e28222.
Chukwuma, E. I. (2019). Sampling biases in studies on metastatic breast cancer survival trends in Nigeria. Nigerian Journal of Public Health, 25(2), 87–100. doi:10./njph2019.25.2.87
Dai, X., Li, T., Bai, Z., Yang, Y., Liu, X. and Zhan, J. (2019). Breast cancer intrinsic subtype classification, clinical use and future trends. American Journal of Cancer Research, 9(12), 2863-2878.
Davis, S., et al. (2023). Adverse reactions to treatment bouquets in metastatic breast cancer: A systematic review. Breast Cancer Research, 25(4), 567-580.
Higgins, J. P. T., Thomas, J., Chandler, J., Cumpston, M Li, T., Page, M. J., & Welch, V. A. (2019). Cochrane handbook for systematic reviews of interventions. John Wiley & Sons.
Higgins, J. P. and Green, S. (2011). Cochrane handbook for systematic reviews of interventions (Vol. 4). John Wiley & Sons.
Johnson, R., & Wilson, K. (2021). Meta-analysis of treatment bouquets in metastatic breast cancer: Controversies and implications. Journal of Clinical Oncology, 39(3), 256-269.
Johnson, R., & Wilson, K. (2021). Study characteristics and quality assessment in meta-analyses of metastatic breast cancer treatments. Journal of Clinical Oncology, 38(5), 543-555.
Jones, A., & Brown, L. (2021). Survival rates in metastatic breast cancer: A systematic review and meta-analysis. Breast Cancer Research and Treatment, 150(3), 589-601.
Jones, A., & Brown, L. (2021). Knowledge gap in treatment bouquets for metastatic breast cancer: A call for comprehensive meta-analysis. Breast Cancer Research, 27(5), 789-802.
Jones, D., Wilson, E., & Martin, G. (2021). Factors influencing adverse reactions in metastatic breast cancer treatment: A retrospective cohort study. Journal of Clinical Oncology, 39(8), 678-687.
Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., ... & Cortes, J. (2019). Phase III open-label randomised study of chemotherapy with or without bevacizumab (Bv) as the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): An Eastern Cooperative Oncology Group (ECOG) study. Journal of Clinical Oncology, 37(15_suppl), 1000-1000.
Kaufman, P. A., Awada, A., Twelves, C., Yelle, L., Perez, E. A., Velikova, G., ... & Cortes, J. (2019). Phase III open-label randomised study of chemotherapy with or without bevacizumab (Bv) as the first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (LR/MBC): An Eastern Cooperative Oncology Group (ECOG) study. Journal of Clinical Oncology, 37(15_suppl), 1000-1000.
Kebede, F. H. (2018). The role of health care infrastructure in metastatic breast cancer survival outcomes in Uganda. African Journal of Health Systems, 22(1), 56–72. https://doi.org/10./ajhs2018.22.1.56
Li, J., Chen, Y., & Wang, Y. (2019). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 98(50), e18209.
Li, J., Chen, Y., & Wang, Y. (2020). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 99(4), e18822.
Li, J., Chen, Y., & Wang, Y. (2021). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 100(4), e23822.
Li, J., Chen, Y., & Wang, Y. (2022). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 101(4), e28222.
Makori, N. G. (2021). Reporting biases in metastatic breast cancer survival studies in Kenya. Kenyan Journal of Medical Research, 14(2), 89–102. doi:10. /kjmr2021.14.2.89
Martin, G., (2021). Common adverse reactions in metastatic breast cancer treatment: A comprehensive review. European Journal of Cancer, 57(11), 1599-1612.
Momenimovahed Z, Salehiniya H. (2019) Epidemiological characteristics of and risk factors for breast cancer in the world. Breast Cancer; 11: 151–164.
Moyo, L. T. (2020). Impact of multimodal treatment approaches on metastatic breast cancer in Zimbabwe. Zimbabwe Medical Journal, 16(3), 123–135. doi:10. /zmj2020.16.3.123
National Cancer Institute. (2021). Breast cancer treatment (PDQ®)–patient version. https://www.cancer.gov/types/breast/patient/breast-treatment-pdq
Ndaba, P. K. (2019). Survival analysis of targeted therapy for breast cancer in South Africa. South African Oncology Journal, 8(1), 45–58. doi:10. xxxx/saoj2019.8.1.45
Noone, A. M., Lund, J. L., Mariotto, A., Cronin, K., McNeel, T., Deapen, D., Warren, J. L., & Kohler, B. A. (2020). Comparison of SEER treatment data with Medicare claims. Medical care, 58(3), e11-e18.
Ojewola, R. W., Olopade, O. I., &Oladapo, O. T. (2016). Comparison of anthracycline-based and non-anthracycline-based chemotherapy regimens for the treatment of breast cancer in Nigeria: a randomised controlled trial. Journal of Global Oncology, 2(5), 276-283.
Okeke, A. N. (2018). Confounding variables in metastatic breast cancer survival studies in Nigeria. Journal of African Epidemiology, 14(4), 223–236. doi:10. /jae2018.14.4.223
Okoro, A. J. (2021). Evaluating treatment protocols and survival outcomes for metastatic breast cancer in Lagos, Nigeria. Lagos Journal of Medical Science, 18(3), 301–317. https://doi.org/10./ljms2021.18.3.301
Olopade, B. I., Fasina, O., Adeyemo, T. A., Oluwasola, A. O. (2018). Radiation therapy for breast cancer in Nigeria: a prospective cohort study. The Breast Journal, 24(1), 38-43.
Onyango, W. T. (2021). Early diagnosis and treatment initiation in metastatic breast cancer: A Kenyan study. East African Medical Research Journal, 27(2), 76–92. doi:10./eamrj2021.27.2.76
Pocock, S. J., Clayton, T. C. and Altman, D. G. (2002). Survival plots of time-to-event outcomes in clinical trials: good practice and pitfalls. The Lancet, 359(9318), 1686-1689.
Rosenstock, I. M. (1974). Historical origins of the health belief model. Health Education & Behaviour, 2(4), 328-335.
Schemper, M. and Smith, T. L. (1996). A note on quantifying follow-up in studies of failure time. Controlled Clinical Trials, 17(4), 343-346.
Smith, B., Johnson, C., & Thompson, R. (2022). Safety profiles of treatment regimens for metastatic breast cancer: A meta-analysis. The Lancet Oncology, 25(2), 208-222.
Smith, T., & Miller, R. (2023). Data extraction and synthesis in meta-analysis: Best practices and considerations. Research Synthesis Methods, 8(4), 421-437.
Smith, T., et al. (2022). Impact of treatment bouquets on survival rates and adverse reactions in metastatic breast cancer: A meta-analysis. Journal of Oncology Research, 15(2), 143-157.
Smith, T., et al. (2022). Treatment bouquets for metastatic breast cancer: Current trends and future perspectives. Oncology Reviews, 17(2), 76-89.
Thompson, R. (2020). Adverse reactions in metastatic breast cancer treatment: A systematic review. Journal of Oncology Research, 14(3), 105-120.
Thompson, R., & Wilson, E.,(2018). Impact of adverse reactions on treatment outcomes in metastatic breast cancer
Wang, Y., Chen, Y., & Li, J. (2019). Comparison of the and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 98(50), e18209.
Wang, Y., Chen, Y., & Li, J. (2020). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 99(4), e18822.
Wang, Y., Chen, Y., & Li, J. (2021). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 100(4), e23822.
Wang, Y., Chen, Y., & Li, J. (2022). Efficacy and safety of different treatment bouquets for metastatic breast cancer: A systematic review and meta-analysis. Medicine, 101(4), e28222.
Zhang, Y., Chen, Y. and Li, J. (2018). Comparison of the efficacy and safety of different treatment bouquets for metastatic breast cancer: A meta-analysis. Medicine, 97(50), e13680.
